Following the publication of a new study showing that the HPV vaccine combats strains of 92% of cancer species associated with human papillomavirus, the U.S. Ministry of Health recommends vaccination of all preteens aged 11/12.
“Non-HPV cancers are at our fingertips, but we need to act quickly to improve the vaccination rates,” said 22 of the US Health minister’s assistant. Application following the publication of a new study carried out by the United States Centre for Disease Control (CDC), revealing that 92% of human papillomavirus-related cancers can prevent vaccination.
34 800 cases of HPV related cancers in the USA between 2012 and 2016
For this large-scale research, scientists researched their cancer centre registers, as well as the National Epidemiological Cancer monitoring programme between 2012 and 2016. Result? Vagina, penis, anus, cervix, throat and throat pain… In the analysed period, 34 800 cases of HPV-related cancers were recorded in the USA.
According to the study, 92% of these cancers were caused by HPV strains against which the vaccine fights.
In France, only 29.4% of girls are vaccinated
Therefore, the US Ministry of Health intends to extend the national immunisation scope to 80% and recommend that all pre-teens be vaccinated at 11 or 12 years of age.
However, according to the study, only 51% of them received all of the recommended doses. With regard to HPV vaccination, France is still under these indicators.
In France, patients aged between 11 and 14 and 15 to 19 years of age are advised to be vaccinated against the HPV vaccine. The European immunisation Week, which took place from 24 to 30 On April 2019, public health revealed in France that only 29.4% of 15-year-old girls born in 2003 were the first dose of the vaccine compared with 26.2% in 2018.
Source: The vaccine may prevent HPV-induced cancers 92%, CDC, 22 August 2019